Market Overview:
Charcot-Marie-Tooth disease is a group of inherited motor and sensory neuropathies that cause muscle weakening and atrophy, mainly within distal muscles of the legs and forearms. Charcot-Marie-Tooth disease treatment aims to manage symptoms and improve mobility and nerve conduction velocity. The treatments include physical therapy, occupational therapy, ankle-foot orthosis and medication.
Market key trends:
One of the key trends in the Charcot-Marie-Tooth disease treatment market is increasing research and development for finding effective treatment options. Currently available treatment options only manage symptoms but do not cure the disease. Research is underway to develop gene therapy and drugs that can slow down progression of the disease. In 2020, Phase 1/2 study was initiated by Addex Therapeutics to evaluate efficacy and safety of dipraglurant in Charcot-Marie-Tooth disease patients. Many pharmaceutical companies are also collaborating with research institutes to develop novel treatment approaches for Charcot-Marie-Tooth disease. This is expected to bring more effective treatment options and drive the market growth over the forecast period.
The global Charcot-Marie-Tooth Disease Market Demand is estimated to be valued at US$ 793.9 Mn in 2023 and is expected to exhibit a CAGR of 23.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global Charcot-Marie-Tooth Disease market is segmented by type, treatment, and end user. By type, Charcot-Marie-Tooth Disease Type 1A accounts for the largest market share owing to its high prevalence rate globally. The segment is expected to continue its dominance during the forecast period attributable to the lack of effective treatment options and increasing research initiatives focused on drug development for CMT1A.
By treatment, the drug therapy segment holds the largest share as there are prescription drugs available to manage the symptoms of the disease effectively. However, the physical therapy segment is likely to witness the fastest growth during the forecast period due to the rising adoption of physical exercises and therapies as mainstream treatment approaches.
Key Takeaways
The US market dominates with the largest revenue share owing to the presence of advanced healthcare infrastructure and high treatment costs. Europe holds the second position and is expected to grow at a substantial CAGR during the forecast period driven by growing R&D funding for rare disease research.
Asia Pacific is anticipated to register the fastest growth fueled by increasing healthcare spending, rising awareness about CMT, and growing disposable income.
Key players operating in the Charcot-Marie-Tooth Disease market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. Major players are focused on developing regenerative therapies and stem cell technologies to effectively treat CMT.
